These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1714969)

  • 1. Effect of the addition of estrogen to medical castration on prostatic size, symptoms, histology and serum prostate specific antigen in 4 men with benign prostatic hypertrophy.
    Levine AC; Kirschenbaum A; Droller M; Gabrilove JL
    J Urol; 1991 Sep; 146(3):790-3. PubMed ID: 1714969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of long-acting gonadotropin-releasing hormone analog (leuprolide) therapy on prostatic size and symptoms in 15 men with benign prostatic hypertrophy.
    Gabrilove JL; Levine AC; Kirschenbaum A; Droller M
    J Clin Endocrinol Metab; 1989 Sep; 69(3):629-32. PubMed ID: 2474565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum prostate-antigen levels in patients with benign prostatic hypertrophy treated with leuprolide.
    Levine AC; Kirschenbaum A; Kaplan P; Droller MA; Gabrilove JL
    Urology; 1989 Jul; 34(1):10-3. PubMed ID: 2473567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a GnRH analogue (leuprolide) on benign prostatic hypertrophy.
    Gabrilove JL; Levine AC; Kirschenbaum A; Droller M
    J Clin Endocrinol Metab; 1987 Jun; 64(6):1331-3. PubMed ID: 2437142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia.
    Weber JP; Oesterling JE; Peters CA; Partin AW; Chan DW; Walsh PC
    J Urol; 1989 Apr; 141(4):987-92. PubMed ID: 2467015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia.
    Peters CA; Walsh PC
    N Engl J Med; 1987 Sep; 317(10):599-604. PubMed ID: 2441256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of urinary retention due to benign prostatic hyperplasia using luteinizing hormone-releasing hormone agonist.
    Schlegel PN; Brendler CB
    Urology; 1989 Aug; 34(2):69-72. PubMed ID: 2474882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage.
    Rick FG; Szalontay L; Schally AV; Block NL; Nadji M; Szepeshazi K; Vidaurre I; Zarandi M; Kovacs M; Rekasi Z
    J Urol; 2012 Apr; 187(4):1498-504. PubMed ID: 22341819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of prostate volume, prostate-specific antigen, and testosterone to flutamide in men with benign prostatic hyperplasia.
    Stone NN; Clejan SJ
    J Androl; 1991; 12(6):376-80. PubMed ID: 1722793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of benign prostatic hypertrophy by a long-acting gonadotropin-releasing hormone analogue: 1-year experience.
    Matzkin H; Chen J; Lewysohn O; Braf Z
    J Urol; 1991 Feb; 145(2):309-12. PubMed ID: 1703239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer.
    Warner B; Worgul TJ; Drago J; Demers L; Dufau M; Max D; Santen RJ
    J Clin Invest; 1983 Jun; 71(6):1842-53. PubMed ID: 6408125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate.
    Santen RJ; Warner B
    Urology; 1985 Feb; 25(2 Suppl):53-7. PubMed ID: 3918377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid androgen cycling as treatment for patients with prostate cancer.
    Feltquate D; Nordquist L; Eicher C; Morris M; Smaletz O; Slovin S; Curley T; Wilton A; Fleisher M; Heller G; Scher HI
    Clin Cancer Res; 2006 Dec; 12(24):7414-21. PubMed ID: 17189414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LHRH agonists. A nonsurgical treatment for benign prostatic hyperplasia.
    Oesterling JE
    J Androl; 1991; 12(6):381-8. PubMed ID: 1722794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer.
    Yu EY; Getzenberg RH; Coss CC; Gittelman MM; Keane T; Tutrone R; Belkoff L; Given R; Bass J; Chu F; Gambla M; Gaylis F; Bailen J; Hancock ML; Smith J; Dalton JT; Steiner MS
    Eur Urol; 2015 Feb; 67(2):334-41. PubMed ID: 24968970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the gonadotropin-releasing hormone agonist [D-leu6, desgly-NH2(10), proethylamide9]-GnRH (leuprolide) on R3327-G rat prostatic tumor growth.
    Pollack A; Block NL; Stover BJ; Fuentes MP; Irvin GL
    J Urol; 1984 Feb; 131(2):399-403. PubMed ID: 6422059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen suppression by a gonadotropin releasing hormone analogue in patients with metastatic carcinoma of the prostate.
    Smith JA
    J Urol; 1984 Jun; 131(6):1110-2. PubMed ID: 6427478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation among prostate stroma, plasma estrogen levels, and urinary estrogen excretion in patients with benign prostatic hypertrophy.
    Seppelt U
    J Clin Endocrinol Metab; 1978 Dec; 47(6):1230-5. PubMed ID: 95629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine environment of benign prostatic hyperplasia: prostate size and volume are correlated with serum estrogen concentration.
    Suzuki K; Ito K; Ichinose Y; Kurokawa K; Suzuki T; Imai K; Yamanaka H; Honma S
    Scand J Urol Nephrol; 1995 Mar; 29(1):65-8. PubMed ID: 7542400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.